Medtronic Annualized CHF Sales Of $300 Mil. Driven By Physician Training
This article was originally published in The Gray Sheet
Executive Summary
Medtronic capitalized on its first-mover advantage with a cardiac resynchronization device for congestive heart failure by aggressively training physicians with its InSync biventricular pacer
You may also be interested in...
Medtronic Licensing Deal With Abbott Is Hawkins’ First Test: Results Pending
William Hawkins' initial stamp on Medtronic's struggling AVE vascular business includes a licensing deal with Abbott Laboratories for a drug-eluting stent compound and an unrelated restructuring of the operating unit, both announced May 9
Guidant Stresses Rapid Contak Physician Training To Make Up For Lost Time
Guidant has set a goal of training at least 800 physicians on use of its Contak CD by the end of June. The implantable cardioverter defibrillator was approved May 2 for resynchronization therapy to treat heart failure
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.